Approved in June 2017 by the U.S. Food and Drug Administration and launched commercially in-country in October 2018, 5-Aminolevulinic Acid (also known as 5-ALA, and composed of aminolevulinic acid hydrochloride) is an optical imaging agent for use in patients with high-grade gliomas. Nicknamed the “pink drink,” 5-ALA is a surgical…...
Brain Cancer Awareness Month
In recognition of Brian Cancer Awareness Month, the National Foundation for Cancer Research today offers up a rather in depth overview of a handful of innovative technologies being explored in labs to address the terrible disease class. Although brain cancer only makes up 1.4% of all new cancer cases, the…...
Medical Coalition Led Largely by NFCR Unites to Battle Glioblastoma
Medical knowledge of glioblastoma multiforme (GBM), the deadliest form of brain cancer, has grown exponentially, but has not resulted in marked improvements in treatment for patients. Addressing this is GBM AGILE (GBM Adaptive Global Innovative Learning Environment), a global medical and scientific coalition that is the first platform trial for…...
Brain Cancer Surgery: Thriving in Recovery
Brain cancer is a formidable adversary in the world of oncology. Against substantial odds, patients work with dedicated doctors to mount a counter offensive. The road to recovery is, to no one’s astonishment, arduous, as brain surgery exposes the very epicenter of our being, behavior, personality, motor skills and memory.…...
NFCR’s Genomics Newsroom: New genes linked to increased risk of ovarian and brain cancer
What is “genomics”? Cancer develops when genetic material (DNA) becomes damaged or changed. We know some cancer causing genetic changes are acquired (i.e. smoking), while others are inherited. Studying cancer genomics explores the differences between cancer cells and normal cells. Advances in understanding how cancer behaves at a genomic and…...